本课题组由临床与基础研究两个核心团队构成，形成紧密协作、优势互补的科研架构。临床团队由三位风湿免疫科主治医生领衔，辅以多名专业型临床医学研究生，具备扎实的临床诊疗经验和丰富的患者管理能力；基础研究团队则由三位博士研究生和两名硕士研究生组成，专注于疾病机制的深度解析与创新疗法的探索。团队成员在各自专业领域内充分发挥优势，通过高效的跨学科协作，推动多项研究工作的深入开展。

       课题组内部学术氛围浓厚，注重开放交流与创新思维，同时定期开展形式多样的团建活动，旨在为团队成员提供身心放松的机会，营造积极、健康的工作环境，以持续激发科研活力。

       团队研究方向聚焦于原发性干燥综合征（pSS）及代谢性炎症疾病的前沿探索，致力于揭示pSS的发病机制，并开发早期诊断与精准治疗的创新策略。目前，我们已成功构建了包含1000余例初诊pSS患者的完整生物样本库，并配套建立了病情随访的信息化管理平台，为深入开展基础与临床研究提供了坚实的数据支撑。

在科研成果方面，团队已在以下领域取得显著进展：

人群特征研究：通过系统分析，描绘了中国pSS患者不同脏器受累的群体画像，为疾病分型与个体化诊疗提供了重要依据。

诊断机制突破：提出了pSS的全新发病机制，探索并验证了具有潜力的早期诊断生物标志物，为临床早期干预提供了理论基础。

治疗策略创新：在治疗方案的优化与新疗法的开发上取得了初步成果，展现了在转化医学研究中的前瞻性。

预后风险模型：在多个风湿病不良预后的风险预测模型构建中取得了一定成效，为临床风险评估与管理提供了实用工具。

相关研究成果已在欧洲风湿病联盟（EULAR）、美国风湿病协会（ACR）及中华医学会风湿病学分会等国际与国内权威学术会议上多次进行汇报交流，体现了团队在风湿免疫领域的活跃度与影响力。

长期深耕“免疫与炎症”领域研究，近年来重点聚焦原发性干燥综合征的发病机制解析与代谢性炎症在自身免疫病中的作用机理探索；同时结合临床实践经验，系统开展结缔组织疾病不同脏器受累的早期诊断标志物筛选及新型治疗策略的临床转化研究。主持国家自然科学基金、上海市科委、上海市卫健委等各级科研课题及人才计划项目10余项，以第一作者或通讯作者身份发表SCI论文20余篇、中文核心期刊论文8篇，获批4项专利。

主持包括国家自然科学基金、上海市科委、上海市卫健委等各级各类课题及人才计划10余项，部分如下：

1. 国家自然科学基金青年项目，编号81801601，循环miR-30c调控I型干扰素信号参与干燥综合征发病的机制研究；

2. 上海市科委医学创新研究项目，编号20Y11911600，血浆外泌体miR29作为干燥综合征合并间质性肺病分子标记物的应用研究；

3. 上海市自然科学基金，编号25ZR1401321，IL-27high巨噬细胞通过ABCA1介导的胆固醇代谢驱动原发性干燥综合征唾液腺损伤的机制研究

4. 上海市青年科技英才扬帆计划项目，项目编号17YF1417200，循环microRNA在干燥综合征诊断和病程中的作用及其机制研究；

5. 上海市“医苑新星”青年医学人才培养资助计划，2020.04—2023.04，评为优秀结业学员；

6. 中央高校基本科研业务费专项基金基础研究人才培养计划，编号22120170199，循环miR30c在干燥综合征诊断和病程中的作用及其机制研究

以第一或通讯作者发表SCI论文20余篇，中文核心期刊6篇，获批专利6项。部分成果如下：

[1]. Han F, Gao R, Fan H, Pu J, Yang L, Wang Y, Song J, Li C, Wang Y, Tang J, Wang X.Telomere length in leukocyte as biomarker for diagnosis of primary Sjögren’s syndrome: a cross-sectional study[J].Clinical Rheumatology, 2025, Epub ahead of print.

[2]. Lin K, Wang Y, Song J, Li B, Wang X, Tian J, Zeng Y, Shahzad M, Tang J, Wang X.Coexistence of VEXAS Syndrome and Chronic Hepatitis B Virus Infection: a Case Report and Literature Review[J].Clinical Reviews in Allergy & Immunology, 2025, 68(1):88.

[3]. Jin H, Song J, Gao R, Sha B, Wang S, Luo P, Yu L, Xu X, Wang X.Telomere Shortening in Interstitial Lung Disease: Challenges and Promises[J].Clinical Respiratory Journal, 2025, 19(7):e70103.

[4]. Song J, Gao R, Han F, Pu J, Liang Y, Wang Y, Wu Z, Pan S, Wu H, Sun Y, Lin K, Tang J, Wang X.Dynamics of serum tumor markers may indicate the progression of interstitial lung disease in Sjögren’s syndrome patients: new roles for old friends[J].Clinical Experimental Medicine, 2025, 25(1):229.

[5]. Chang K, Luo P, Guo Z, Yang L, Pu J, Han F, Cai F, Tang J, Wang X. Lipid Metabolism: An Emerging Player in Sjögren’s Syndrome[J]. Clinical Reviews in Allergy & Immunology, 2025, 68(1): 15.

[6]. Han F, Riaz F, Pu J, Gao R, Yang L, Wang Y, Song J, Liang Y, Wu Z, Li C, Tang J, Xu X, Wang X. Connecting the dots: telomere shortening and rheumatic diseases[J]. Biomolecules, 2024, 14(10): 1261.

[7]. Yang L, Liang Y, Pu J, Cai L, Gao R, Han F, Chang K, Pan S, Wu Z, Zhang Y, Wang Y, Song J, Wu H, Tang J, Wang X. Dysregulated serum lipid profile is associated with inflammation and disease activity in primary Sjögren's syndrome: a retrospective study in China[J]. Immunology Letters, 2024, 267: 106865.

[8]. Wang Y, Riaz F, Wang W, Pu J, Liang Y, Wu Z, Pan S, Song J, Yang L, Zhang Y, Wu H, Han F, Tang J, Wang X. Functional significance of DNA methylation: epigenetic insights into Sjögren’s syndrome[J]. Frontiers in Immunology, 2024, 15: 1289492.

[9]. Yang L., Pu J., Cai F., Zhang Y., Gao R., Zhuang S., Wang X*. Chronic Epstein-Barr virus infection: A potential junction between primary Sjögren’s syndrome and lymphoma. Cytokine, 2023, 168: 156227.

[10]. Gao R, Pu J, Wu Z, Tang J, Wang X*. Osteoarthritis or arthritis? Toward undertsanding of primary Sjögren's syndrome patients with arthralgia. J Orthop Surg Res.2023 16;18(1):41 .

[11]. Chen S#, Wang X#, Sun C, Zhao CB, Lin J*. MAGT1 Gene Mutation is Associated with Myositis and CD127 Expression Downregulation. J Clin Immunol. 2022. 43(2):315-318.

[12]. Gao R#, Wu Z#, Xu X#, Pu J, Pan S, Zhang Y, Zhuang S, Yang L, Liang Y, Song J, Tang J*, Wang X*. Predictors of poor prognosis in ANCA-associated vasculitis (AAV): a single-center prospective study of inpatients in China, Clin Exp Med, 2022.

[13]. Zhuang S#, Pu J#, Liang Y, Wu Z, Gao R, Pan S, Song J, Tang J*, Wang X*. Potential Mechanisms of White Peony against Primary Sjögren's Syndrome Based on Network Pharmacology and Molecular Docking, Evid Based Complement Alternat Med, 2022, 2022:5507472.

[14]. Li B, Yan J, Pu J, Tang J, Xu S*, Wang X*. Letter to the Editor Regarding [Esophageal Dysfunction and Systemic Sclerosis: Drugs Should be Kept in Mind, Rheumatol Ther, 2022, 9(4):1241-1243.

[15]. Zhang Y, Zhang L, Wu Z, Tang J*, Wang X*. Relapsing Polychondritis Associated with Miscellaneous Ocular Symptoms and Increased IgA: a Case Report, Iran J Immunol, 2022, 19(1):10.

[16]. Li B, Yan J, Pu J, Tang J, Xu S*, Wang X*. Esophageal Dysfunction in Systemic Sclerosis: An Update, Rheumatology and Therapy, 2021,8(4):1535-1549.

[17]. Gao R#, Xu X#, Wang S#, Pu J, Shi C, Wen S, Zhu Y, Tang J, Wang X*, Yu L*. The efficacy of gabapentin for the treatment of refractory cough associated with interstitial lung disease: study protocol for a randomized, double-blind and placebo-controlled clinical trial, Trials, 2022, 23(1):165.

[18]. Pu J#, Wang X#, Riaz F, Zhang T, Gao R, Pan S, Wu Z, Liang Y, Zhuang S, Tang J*. Effectiveness and Safety of Iguratimod in Treating Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021,12:621208.

[19]. Wang X#, Zhang T#, Guo Z, Pu J, Riaz F, Feng R, Fang X, Song J, Liang Y, Wu Z, Pan S, Tang J*. The Efficiency of Hydroxychloroquine for the Treatment of Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021,12:693796.

[20]. Yao Q#, Wang X#, He W, Song Z, Wang B, Zhang J*, Qin Q*. Circulating microRNA-144-3p and miR-762 are novel biomarkers of Graves' disease, Endocrine, 2019, 65(1):102-109.

[21]. Wang X, Shao X, Liu X, Qin Q, Xu J, Zhang JA*. Dysregulated Interleukin-33/ST2 Pathway Perpetuates Chronic Inflammation in Hashimoto's Thyroiditis, Endocr Metab Immune Disord Drug Targets. 2019, 19(7):1012-1021.

[22]. Wang X, Zhu Y, Li D, Qin Q, Wang Q, Muhali FS, Jiang WJ, Zhang JA*. Polymorphisms of ST2-IL18R1-IL18RAP gene cluster: a new risk for autoimmune thyroid diseases, International Journal of Immunogenetics. 2016, 43(1):18-24.

[23]. Wang X, Wang M, Li H, Lan X, Liu L, Li J, Li Y, Li J, Yi J, Du X, Yan J, Han Y, Zhang F, Liu M, Lu S, Li D*. Upregulation of miR-497 induces hepatic insulin resistance in E3 rats with HFD-MetS by targeting insulin receptor, Molecular and Cellular Endocrinology. 2015, 416(C):57-69.

[24]. Li D#, Wang X#, Lan X, Wang Y, Li H, Zhong N, Holmdahl R, Lu S*. Down-regulation of miR-144 elicits proinflammatory cytokine production by targeting toll-like receptor 2 in nonalcoholic steatohepatitis of high-fat-diet-induced metabolic syndrome E3 rats, Molecular and Cellular Endocrinology. 2015, 402(C):1-12.

[25]. Li D#, Wang X#, Holmdahl R, Lu S*. High expression of liver histone deacetylase 3 contributes to high-fat-diet-induced metabolic syndrome by suppressing the PPAR-gamma and LXR-alpha-pathways in E3 rats, Molecular and Cellular Endocrinology. 2011, 344(1-2):69-80.